+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Lenalidomide"

From
From
Blood Cancer Drugs Global Market Report 2024 - Product Thumbnail Image

Blood Cancer Drugs Global Market Report 2024

  • Report
  • November 2023
  • 175 Pages
  • Global
From
Precision Cancer Therapeutics, 2022 - Product Thumbnail Image

Precision Cancer Therapeutics, 2022

  • Report
  • November 2022
  • 154 Pages
  • Global
From
From
From
From
From
Elotuzumab Emerging Drug Insight and Market Forecast - 2032 - Product Thumbnail Image

Elotuzumab Emerging Drug Insight and Market Forecast - 2032

  • Drug Pipelines
  • December 2022
  • 30 Pages
  • Global
From
From
Revlimid - Product Thumbnail Image

Revlimid

  • Report
  • January 2019
  • 56 Pages
  • Global
From
Isatuximab - Product Thumbnail Image

Isatuximab

  • Report
  • August 2018
  • 20 Pages
  • Global
From
  • 14 Results (Page 1 of 1)
Loading Indicator

Lenalidomide is an immunomodulatory drug used in the treatment of multiple myeloma, myelodysplastic syndromes, and mantle cell lymphoma. It is a derivative of thalidomide, and works by inhibiting tumor growth and angiogenesis. Lenalidomide is also used to treat anemia, a common symptom of cancer. It is taken orally, and is available in both capsule and tablet form. Lenalidomide is a relatively new drug, and is still in the process of being approved for use in many countries. It is currently approved in the United States, Canada, Europe, Australia, and other countries. It is also being studied for use in other types of cancer, such as breast cancer and non-Hodgkin's lymphoma. Lenalidomide is a highly effective drug, and is often used in combination with other drugs to treat cancer. It is also used in combination with chemotherapy and radiation therapy. Lenalidomide is marketed by several companies, including Celgene, Teva Pharmaceuticals, and Mylan. It is also available in generic form from several generic drug manufacturers. Show Less Read more